Cancer Monoclonal Antibodies Market Report 2025

The cancer monoclonal antibodies market size has grown rapidly in recent years. It will grow from $77.88 billion in 2024 to $86.06 billion in 2025 at a compound annual growth rate (CAGR) of 10.5%. The growth in the historic period can be attributed to emerging markets growth, increase in R&D expenditure, increased geriatric population, and increased preference for biological treatments.

The cancer monoclonal antibodies market size is expected to see strong growth in the next few years. It will grow to $113.68 billion in 2029 at a compound annual growth rate (CAGR) of 7.2%. The growth in the forecast period can be attributed to the increasing prevalence of cancer, expanding global access, and a rise in healthcare expenditure will drive the growth. Major trends in the forecast period include product innovation through strategic collaborations, technological advancements, developing humanized cancer monoclonal antibodies, investments in AI to reduce R&D costs and save drug development time, and R&D investments.

The increase in cancer cases worldwide is expected to drive the growth of the cancer monoclonal antibody market. For example, in July 2024, the Australian Institute of Health and Welfare, a government agency in Australia, reported that the number of diagnosed cancer cases in Australia rose from 160,570 in 2022 to 164,694 in 2023, indicating a significant increase over the year. This trend emphasizes the rising prevalence of cancer within the country. The four most prevalent types of cancer globally are lung, prostate, bowel, and female breast cancer, which together account for 43 percent of all new cancer cases. Therefore, the global rise in cancer incidence is anticipated to enhance the demand for the cancer monoclonal antibody market.

Growing healthcare expenditures are predicted to propel the growth of the cancer monoclonal antibodies market. Healthcare expenditures encompass the total amount spent on healthcare-related services, products, and activities within a defined timeframe, typically assessed at the individual, community, national, or global level. Increased funding in healthcare can facilitate the development, accessibility, and research of monoclonal antibody treatments, while also supporting the adoption of advanced technologies for their production and delivery. For instance, in 2022, the Office for National Statistics, a UK-based national statistics organization, reported that healthcare expenditure in the UK reached approximately $354.88 billion (£283 billion), representing a nominal increase of 0.7% compared to 2021. Hence, the rising healthcare expenditure is set to drive the growth of the cancer monoclonal antibodies market in the future.

Companies within the cancer monoclonal antibody market are actively pursuing product innovation through strategic collaborations as a means to sustain competitiveness in the industry. To navigate the increasingly competitive landscape, these companies are not only focusing on developing innovative products but also engaging in partnerships aimed at sharing skills and expertise. While partnerships with academic and research institutions have been a traditional practice in this sector, the trend of collaboration has notably intensified in recent years. As an illustration, in March 2023, BioNTech SE, a German biotechnology research company, entered into a partnership with OncoC4, Inc. This collaboration aims to jointly develop and commercialize an innovative checkpoint antibody targeting various solid tumor indications. BioNTech will gain an exclusive worldwide license for the ONC-392 anti-CTLA-4 monoclonal antibody from OncoC4. The partnership outlines plans for joint development in solid tumor indications, including the initiation of a Phase 3 trial in 2023. Additionally, BioNTech will explore combination therapies and provide a $200 million upfront payment, alongside royalty payments, and potential milestone payments to OncoC4. OncoC4, Inc., based in the US, specializes in the clinical-stage development of biopharmaceuticals for cancer treatment.

Companies are directing their efforts toward pioneering biologic therapies, such as EPKINLY, to reinforce their market position. EPKINLY stands as an FDA-approved bispecific antibody designed for the treatment of advanced lymphoma. In a significant development in May 2023, AbbVie Inc., a US-based biopharmaceutical company, secured approval from the U.S. Food and Drug Administration (FDA) for EPKINLYTM (epcoritamab-bysp). This groundbreaking approval marks EPKINLY as the first and sole T-cell engaging bispecific antibody designated for treating adult patients grappling with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), including instances originating from indolent lymphoma, and high-grade B-cell lymphoma (HGBL) who have undergone at least two rounds of systemic therapies.

In March 2024, Johnson & Johnson, a multinational corporation based in the U.S. that develops and manufactures medical devices and pharmaceuticals, acquired Ambrx for $2 billion. This acquisition is intended to strengthen Johnson & Johnson's oncology pipeline by advancing next-generation antibody-drug conjugates, specifically for the treatment of metastatic castration-resistant prostate cancer. Ambrx is a biotechnology company located in the U.S. that specializes in antibody-drug conjugates.

Major companies operating in the cancer monoclonal antibodies market include F. Hoffmann-La Roche Ltd, Merck & Co., Inc, Bristol Myers Squibb Company, Johnson & Johnson, Amgen Inc, AstraZeneca plc, Eli Lilly and Company, Pfizer Inc, Regeneron Pharmaceuticals Inc, Sanofi S.A, Innovent Biologics, Sino biological, Shanghai Henlius Biotech, Intas bio, Zydus Cadila, Ranbaxy, Takeda pharmaceuticals, AbbVie Inc, Biogen Idec, Bayer AG, Novartis AG, BiosanaPharma, WuXi, GlaxoSmithKline, Teva UK Limited, Abbott Laboratories, Fujifilm, Procos SpA, BSP Pharmaceuticals, Genmab, Insysbio, Gilead Sciences, Eurofarma, BIONOVIS BRASIL, Ache, Libbs Farmaceutica, Julphar, Spimaco Addwaeih, Hikma Pharmaceuticals, Tabuk, Novo Nordisk, BBI Solutions, APC Pharma, EPICIO, Medical Union Pharmaceuticals, South Egypt Drug Industries Co. Pharmaceutical, Vacsera Pharma, Aspen Pharmacare, Amoun Pharmaceuticals CO Ltd, 54gene, Baxter International, Altis Biologics, Cipla Medpro South Africa, Genzyme.

North America was the largest region in the cancer monoclonal antibodies market in 2024. The regions covered in the cancer monoclonal antibodies market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the cancer monoclonal antibodies market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain.

Cancer monoclonal antibodies are lab-created proteins designed to bind to specific targets, such as antigens on cancer cells. Each antibody is tailored to bind to a single antigen, resulting in a diverse range of monoclonal antibodies.

Key types of monoclonal antibody therapies for cancer include bevacizumab (Avastin), rituximab (Rituxan), trastuzumab (Herceptin), cetuximab (Erbitux), and panitumumab (Vectibix). Avastin, for example, is utilized for treating wet age-related macular degeneration and diabetic eye problems. Applications span breast cancer, blood cancer, liver cancer, brain cancer, colorectal cancer, and more. These therapies are utilized across various sectors, including hospitals, clinics, research laboratories, pharmacies, and others.

The cancer monoclonal antibodies market research report is one of a series of new reports that provides cancer monoclonal antibodies market statistics, such as cancer monoclonal antibodies industry global market size, regional shares, competitors with a cancer monoclonal antibodies market share, detailed cancer monoclonal antibodies market segments, market trends and opportunities, and any other information you may require to thrive in the ca This cancer monoclonal antibodies market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The cancer monoclonal antibody market consists of sales of pembrolizumab, blinatumomab, casirivimab, and imdevimab. Values in this market are "factory gate values," that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.